Immunome, Inc. (IMNM)
Market Cap | 701.64M |
Revenue (ttm) | 12.68M |
Net Income (ttm) | -232.03M |
Shares Out | 59.97M |
EPS (ttm) | -7.55 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 597,611 |
Open | 12.22 |
Previous Close | 12.20 |
Day's Range | 11.50 - 12.22 |
52-Week Range | 6.13 - 30.96 |
Beta | 1.85 |
Analysts | Strong Buy |
Price Target | 29.75 (+154.27%) |
Earnings Date | Aug 7, 2024 |
About IMNM
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and i... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price forecast is $29.75, which is an increase of 154.27% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/w/b/press2-2500967.jpg)
Immunome Appoints Phil Tsai as Chief Technical Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen...
![](https://cdn.snapi.dev/images/v1/y/f/press15-2439471.jpg)
Immunome Announces Completion of Purchase of Assets from Atreca
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion...
![](https://cdn.snapi.dev/images/v1/y/h/press16-2436919.jpg)
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion ...
![](https://cdn.snapi.dev/images/v1/e/k/press13-2429238.jpg)
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
![](https://cdn.snapi.dev/images/v1/k/t/conf3-2417869.jpg)
Immunome to Present at 2024 Bank of America Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...
![](https://cdn.snapi.dev/images/v1/w/k/press19-2405895.jpg)
Immunome Appoints Kinney Horn as Chief Business Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen...
![](https://cdn.snapi.dev/images/v1/e/d/press18-2390953.jpg)
Immunome Appoints Sandra M. Swain to Board of Directors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen...
![](https://cdn.snapi.dev/images/v1/k/e/conf6-2358403.jpg)
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p...
![](https://cdn.snapi.dev/images/v1/y/t/press14-2347176.jpg)
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
![](https://cdn.snapi.dev/images/v1/i/8/press3-2341647.jpg)
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful...
![](https://cdn.snapi.dev/images/v1/h/h/press3-2328304.jpg)
Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies
EDINBURGH, Scotland--(BUSINESS WIRE)--Arrayjet, a leading provider of inkjet liquid-handling solutions, today announced that its ArrayPlex™ discovery platform has been selected by Immunome, Inc. (NASD...
![](https://cdn.snapi.dev/images/v1/5/7/press20-2312953.jpg)
Immunome to Participate in the Leerink Partners Global Biopharma Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...
![](https://cdn.snapi.dev/images/v1/v/h/press15-2303433.jpg)
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...
![](https://cdn.snapi.dev/images/v1/y/y/press12-2283502.jpg)
Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announc...
![](https://cdn.snapi.dev/images/v1/i/p/press4-2281082.jpg)
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced...
![](https://cdn.snapi.dev/images/v1/b/r/press11-2275023.jpg)
Immunome Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced...
![](https://cdn.snapi.dev/images/v1/i/x/press5-2274494.jpg)
Immunome Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced...
![](https://cdn.snapi.dev/images/v1/y/2/press4-2261975.jpg)
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
BOTHELL, Wash. & MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, to...
![](https://cdn.snapi.dev/images/v1/e/n/conf2-2259711.jpg)
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members o...
![](https://cdn.snapi.dev/images/v1/3/f/press18-2219874.jpg)
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
BOTHELL, Wash. & SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worl...
![](https://cdn.snapi.dev/images/v1/p/s/press20-2216303.jpg)
Immunome Appoints Phil Roberts as Chief Technical Officer
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointmen...
![](https://cdn.snapi.dev/images/v1/p/i/conf9-2214568.jpg)
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg...
![](https://cdn.snapi.dev/images/v1/w/k/press11-2213083.jpg)
Immunome Appoints Carol A. Schafer to Board of Directors
BOTHELL, Wash. & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
![](https://cdn.snapi.dev/images/v1/g/m/press19-2207989.jpg)
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it ...
![](https://cdn.snapi.dev/images/v1/c/v/conf18-2152063.jpg)
Immunome to Present at the Stifel 2023 Healthcare Conference
SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Cla...